Fosun Pharma increases guarantees for subsidiaries

Shanghai Fosun Pharmaceutical Group (SSE:600196) announced today it is providing new guarantees for its controlling subsidiaries, further expanding its financial commitments within the group. The guarantees include providing a RMB 170 million guarantee to Industrial and Commercial Bank of China (ICBC) for its subsidiary, Fosun Pharmaceutical Industry. A second guarantee will cover up to RMB 100 million for Fosun Yali Feng with HSBC bank, backed by a pledge of equity from Fosun Antigene and its shareholders. An additional RMB 15 million guarantee is extended by Beijing Weichi for Beijing Beiling via Beijing Rural Commercial Bank. As of March 20, 2025, Fosun Pharma's total guarantees for subsidiaries are approximately RMB 890.88 million for Fosun Pharmaceutical Industry, RMB 71.19 million for Fosun Yali Feng, and RMB 2 million for Beijing Beiling. Fosun Pharma states that there are no overdue guarantees within the group. These guarantees fall within previously approved parameters.